SNEAK PREVIEW: BioInvest Digest launches

January 2, 2013 | Jim Lane

As a signature event in launching our year-long “Biofuels 2013, the Year of Capital” coverage — the new BioInvest Digest debuts today (1/2/13) at 2pm ET, to serve those investing or lending in industrial biotechnology.

In BioInvest Digest, we’ll focus on who is investing where, when, why and how.

SNEAK PREVIEW

THE CASE: The New Milo-naires: Corn, sorghum and the Invisible Hand of the Biofuels Market

Gevo initiates stock repurchase

Biofuels Digest Index: 2013′s start, in detail

Amyris secures $42.25 million in financing

REG extends debt for REG Newton, pays off debt for REG Seneca

BioInvest Digest at-a-glance

INSIGHT. Each lead article — “The Case” — looks deeply and critically at new strategies, opportunities and cautionary tales.

BioInvest-logo2

And, for busy professionals, a concise and complete news resource delivering “news you can use” summaries that take up five minutes or less of your time each issue.

You’ll see Venture News, Investor News, Deployment News, and Policy News – plus, expanded coverage of finance and investing with our expanded Biofuels Digest Index™ stock index coverage for public equities, and expanded coverage of private offerings.

SCALE. As industrial biotech ventures move from pilot to player, and spreads globally through licensing — opportunity abounds, and risk is everywhere you look. Capital-raising activity is increasing sharply, and will increase more as projects move towards global deployment at industrial scale.

RISK. What’s the best way to evaluate ventures? What structures best manage technology, market, price, management, feedstock, and policy risk? What projects are feasible, and when, based on what parameters?

For example, in our debut issue, we look at transformations in the structuring on inputs, in the first-gen ethanol fleet, that will dramatically change the way these projects return on investment — and, in turn, alter the path of transition to next-gen biofuels.

HAVES and HAVE-NOTS. Most importantly, there is information risk and information asymmetries — and the corresponding arbitrage between the haves and the have-nots, when it comes to data and perspective. With the era of deregulated capital raising and crowdfunding upon us, access to information, we believe, has never been more important.

BRIDGING THE GAP. Seeking to bridge the information gap between what is true and what is known — we happily present you the weekly BioInvest Digest, published each Wednesday — available at the everyday low price of free.